Karyopharm cuts staff amid push to broaden use of blood cancer drug

Cancer drug developer Karyopharm Therapeutics is reducing its workforce and streamlining its clinical development plan, joining a list of nearly 100 other drugmakers to turn to layoffs in 2023.